METROPOLIS - Fundamental Analysis: Financial Health & Valuation

Last Updated Time : 05 Nov 25, 7:43 am

Fundamental Rating: 3.4

Metropolis Healthcare shows moderate profitability and low debt, but its valuation is stretched and growth metrics are weak. Long-term holding is viable only if accumulated near support levels and supported by margin improvement.

📊 Financial Overview

• Revenue: ₹1,404 Cr (TTM) — stable growth in diagnostics and pathology services

  Value Research

• Profitability: PAT improved to ₹35.6 Cr from ₹23.8 Cr QoQ; EPS at ₹25.1
• Margins: ROCE at 13.4%, ROE at 10.5% — moderate efficiency
• Debt Profile: Debt-to-equity ratio of 0.14 — low leverage
• Dividend Yield: 0.00% — no income return for shareholders

📈 Valuation Metrics

• P/E Ratio: 79.3 — significantly above industry average of 37.4
• P/B Ratio: ~8.2 — premium valuation relative to book value ₹240
• PEG Ratio: -5.67 — negative due to weak earnings growth
• Intrinsic Value: Estimated around ₹1,700–₹1,800 based on normalized earnings

  Value Research

🏢 Business Model & Competitive Edge

• Core Operations: Leading diagnostics chain offering pathology and wellness testing across India
• Moat: Strong brand in urban markets, high-quality lab infrastructure, and digital integration
• Growth Drivers: Expansion in Tier 2/3 cities, preventive health packages, and B2B hospital partnerships

📌 Entry Zone Recommendation

• Suggested Entry: ₹1,850–₹1,900 — near DMA200 and RSI support zone
• Technical Indicators: RSI at 45.9 (neutral), MACD negative — short-term weakness

📈 Long-Term Holding Guidance

• Hold cautiously; wait for margin expansion and volume growth to justify valuation
• Monitor competitive pressure from new-age diagnostic startups and pricing trends

✅ Positive

• Low debt and improving quarterly profits
• Strong brand and digital infrastructure
• DII holding increased by 0.70%

⚠️ Limitation

• High P/E and negative PEG ratio
• FII holding declined by 0.31%
• MACD indicates short-term bearish trend

📰 Company Negative News

• Stock has underperformed broader healthcare index due to valuation concerns and muted growth

🌟 Company Positive News

• Q4 FY25 PAT up 13.8% QoQ; revenue growth driven by wellness segment and B2B channels

  Value Research

🏭 Industry

• Diagnostics industry P/E at 37.4 — Metropolis trades at a premium
• Sector driven by preventive care, insurance coverage, and digital health adoption

🧾 Conclusion

• Metropolis Healthcare is a stable diagnostics player with moderate fundamentals and stretched valuation
• Accumulate only near support zones; long-term holding depends on margin and volume growth

Sources

Value Research

Value Research

Stock Analysis

StockAnalysis

stockinsights.ai

StockInsights